Research

Zacks Small Cap Research – POET: With Cash at $40 Million, POET looks Beyond Providing Samples to Major New Customers and Prepares for Production. – Go Health Pro

by

By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT POET Inks Deal With Mitsubishi to Design and Market 1.6T and 3.2T Engines Together On Sept. 19th, POET (NASDAQ:POET) announced a deal with Mitsubishi Electric to co-develop integrated optical engine chipsets for 3.2T pluggable transceivers. Mitsubishi Electric will contribute its 400G Electro-absorption Modulator Integrated Lasers … Read more

Article 43 of the EU Data Act from a Research Perspective – Go Health Pro

by
Article 43 of the EU Data Act from a Research Perspective – Go Health Pro

       Author: Maryna Manteghi, PhD researcher, University of Turku, Finland.   Photo credit: rjcastillo, via Wikimedia commons   Introduction   The new EU Data Act Regulation, which constitutes one of the essential elements of the European strategy for data, entered into force on 11 January 2024 and will become applicable in September 2025. … Read more

Zacks Small Cap Research – AI from EVAX Improves Trial Results – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company’s AI models, novel targets within … Read more

Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Marburg Virus Outbreak Puts Focus on Soligenix Vaccine Development Soligenix, Inc. (NASDAQ:SNGX) is developing vaccines targeting multiple filoviruses, including MarVax, a heat stable vaccine for protection against Marburg virus. Recent events highlight the importance of the company’s vaccine development program. On October … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Announces Submission of DrugSorb-ATR Application to the FDA – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT DrugSorb-ATR Submission On October 1, 2024, CytoSorbents (NASDAQ:CTSO) announced the submission of its DrugSorb-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (FDA) on September 27, 2024. The goal of this product is to reduce the severity of perioperative … Read more

x